Literature DB >> 6407847

The effects of peritoneal dialysis on the single dose and steady state pharmacokinetics of valproic acid in a uremic epileptic child.

J M Orr, K Farrell, F S Abbott, S Ferguson, W J Godolphin.   

Abstract

The pharmacokinetics of valproic acid (VPA) have been studied during peritoneal dialysis in a uremic male epileptic child following a single 500 mg dose and after multiple doses over 5 months (700 mg daily) of valproic acid as the syrup. Serum level decline was biphasic in both instances with a terminal half-life of 27.2 after the single dose and 10.2 h at steady-state. Total serum clearance was 0.0236 l/h/kg after the single dose and increased to 0.0408 l/h/kg after 5 months. Free (intrinsic) serum clearances were 0.1489 and 0.1518 l/h/kg and serum free fractions were 0.224 and 0.272 respectively for the single dose and steady-state studies. Peritoneal dialysis for periods of 12 or 24 h removed an average of 4.5% of the VPA dose.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6407847     DOI: 10.1007/BF00610060

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  12 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Protein binding of drugs in uremic and normal serum: the role of endogenous binding inhibitors.

Authors:  I Sjöholm; A Kober; I Odar-Cederlöf; O Borgåa
Journal:  Biochem Pharmacol       Date:  1976-05-15       Impact factor: 5.858

3.  Serum protein binding of valproic acid and its displacement by palmitic acid in vitro.

Authors:  A Monks; A Richens
Journal:  Br J Clin Pharmacol       Date:  1979-08       Impact factor: 4.335

4.  Binding of drugs to human serum albumin. XIV. The theoretical basis for the interaction between phenytoin and valproate.

Authors:  A Kober; Y Olsson; I Sjöholm
Journal:  Mol Pharmacol       Date:  1980-09       Impact factor: 4.436

5.  The effect of acetylsalicylic acid on serum free valproate concentrations and valproate clearance in children.

Authors:  K Farrell; J M Orr; F S Abbott; S Ferguson; I Sheppard; W Godolphin; J Bruni
Journal:  J Pediatr       Date:  1982-07       Impact factor: 4.406

6.  Pharmacokinetics of sodium valproate in epileptic patients: prediction of maintenance dosage by single-dose study.

Authors:  G J Schapel; R G Beran; C J Doecke; W J O'Reilly; P A Reece; R H Rischbieth; L N Sansom; P E Stanley
Journal:  Eur J Clin Pharmacol       Date:  1980-01       Impact factor: 2.953

7.  Valproate plasma protein binding in the uremic condition.

Authors:  D Brewster; N C Muir
Journal:  Clin Pharmacol Ther       Date:  1980-01       Impact factor: 6.875

8.  Pharmacokinetics of di-n-propylacetate in epileptic patients.

Authors:  F Schobben; E van der Kleijn; F J Gabreëls
Journal:  Eur J Clin Pharmacol       Date:  1975-02-28       Impact factor: 2.953

9.  Valproic acid analysis in saliva and serum using selected ion monitoring (electron ionization) of the tert.-butyldimethylsilyl derivatives.

Authors:  F S Abbott; R Burton; J Orr; D Wladichuk; S Ferguson; T H Sun
Journal:  J Chromatogr       Date:  1982-02-12

10.  Interaction between valproic acid and aspirin in epileptic children: serum protein binding and metabolic effects.

Authors:  J M Orr; F S Abbott; K Farrell; S Ferguson; I Sheppard; W Godolphin
Journal:  Clin Pharmacol Ther       Date:  1982-05       Impact factor: 6.875

View more
  1 in total

Review 1.  Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide.

Authors:  D Battino; M Estienne; G Avanzini
Journal:  Clin Pharmacokinet       Date:  1995-10       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.